These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 35822666)

  • 1. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation.
    Azab AE; Alesawy MS; Eldehna WM; Elwan A; Eissa IH
    Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200133. PubMed ID: 35822666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
    Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
    Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
    Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
    Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Elwan A; Elkady H
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1093-1114. PubMed ID: 34056992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
    Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
    Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis,
    Taghour MS; Mahdy HA; Gomaa MH; Aglan A; Eldeib MG; Elwan A; Dahab MA; Elkaeed EB; Alsfouk AA; Khalifa MM; Eissa IH; Elkady H
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2063-2077. PubMed ID: 35875937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and biological evaluation of 3-substituted quinazoline-2,4(1
    Hassan A; Mubarak FAF; Shehadi IA; Mosallam AM; Temairk H; Badr M; Abdelmonsef AH
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2189578. PubMed ID: 36919632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition.
    El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM
    Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia.
    Othman EM; Fayed EA; Husseiny EM; Abulkhair HS
    Bioorg Chem; 2022 Oct; 127():105968. PubMed ID: 35728289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
    Alsaif NA; Mahdy HA; Alanazi MM; Obaidullah AJ; Alkahtani HM; Al-Hossaini AM; Al-Mehizi AA; Elwan A; Taghour MS
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100359. PubMed ID: 34862634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking.
    Hassan RA; Hamed MIA; Abdou AM; El-Dash Y
    Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
    Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors.
    Abdallah AE; Mabrouk RR; Al Ward MMS; Eissa SI; Elkaeed EB; Mehany ABM; Abo-Saif MA; El-Feky OA; Alesawy MS; El-Zahabi MA
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):573-591. PubMed ID: 35012403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.
    Alanazi MM; Eissa IH; Alsaif NA; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Elkady H; Elwan A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1760-1782. PubMed ID: 34340610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2.
    Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS
    Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.